Levilimab

DRUG2 trials

Sponsors

Biocad

Conditions

COVID-19Rheumatoid Arthritis

Phase 3

A Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19

CompletedNCT04397562

Start: 2020-04-29End: 2020-08-03Updated: 2021-11-18

A Two-Stage Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Various Doses of Levilimab When Administered Intravenously and Subcutaneously to Healthy Subjects and Subjects With Active Rheumatoid Arthritis

Active, not recruitingNCT05800327

BiocadRheumatoid Arthritis

Start: 2022-12-07End: 2027-12-31Target: 261Updated: 2023-04-05

Related Papers

Extract of oak bark as a selective natural reagent for the spectrophotometric determination of iron (II) in pharmaceutical preparations and blood serum

Rheumatology Science and Practice2025-11-01

The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study

Inflammation Research2021-09-2953 citations